The directors/management could be privy to information that a massive buyout is in discussion and still participate. That is why it is subject to shareholder approval. We decide if they are allowed to participate.
What I would have liked to see on the poster at the stockholm conference is the trial participants split into cohort 1 and 2. Based on the length of time on the trial it can be determined, although I believe 1 participant transferred from cohort 1 to cohort 2 and 1 participant started late in cohort 1. Looking at the individual participants to their matched expected rate of decline, most of cohort 2 are outperforming nearly all matched data. A massive confidence boost for me on the effect the high dose is having. Now let's get this trial underway and make a real difference to people with ALS/MND.
Ann: Trading Halt, page-133
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.010(5.13%) |
Mkt cap ! $99.65M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.5¢ | 19.5¢ | $95.38K | 475.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 135256 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 79851 | 3 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |